Everolimus (Certican) in renal transplantation: a review of clinical trial data, current usage, and future directions

摘要: Abstract The efficacy and tolerability of everolimus have been demonstrated in a number clinical trials, there is also an increasing body experience. after renal transplantation at least equivalent to that mycophenolate mofetil. Studies combining with full- or reduced-dose cyclosporine (CsA) shown CsA exposure can be minimized, without the risk acute rejection, particularly when combined therapeutic drug monitoring. A role for regimens involving elimination calcineurin inhibitors currently being investigated. Everolimus significantly has not enhance CsA-related nephrotoxicity. Adverse events seen trials are generally class-specific include edema, arthralgia, dyslipidemia, impaired wound healing, proteinuria. low incidence malignancy observed everolimus, studies ongoing examine its antitumor effects treatment certain malignancies. It seems likely will continue play development reduced-exposure inhibitor considerable potential improve outcomes transplant recipients, focused perhaps on "old-for-old" recipients patients high poor graft function malignancy. This review considers available data application identifies current future strategies improving transplantation.